Lupin Limited · NSE:LUPIN
Lupin — Q2 FY24 Earnings Presentation
21 slides from Lupin's earnings presentation, Nov 8, 2023
Slide 1: Exchange cover letter for Investor Presentation Q2 FY24
November 8, 2023 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sir/Madam, Sub: Investor Presentation Q2 FY24. Pursuant to Regulation 30(
Slide 2: Investor Presentation Q2 FY24
Investor Presentation Q2 FY24 November 08, 2023
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Q2 FY24 Performance
Q2 FY24 Performance
Slide 5: Q2 FY24: Key Growth Metrics
Q2 FY24: Key Growth Metrics Strong execution on all fronts Key Metrics Business Performance INR mn India North America 49,392 mn 16,915 mn 18,666 mn Sales 7% YoY 40% YoY 21% YoY 9,231 mn 18.7% Growth Markets EMEA EBITDA1 Margin 4,378 mn 4,759 mn 2% YoY 24% YoY 113% YoY API ROW 4,897 mn 9.9% margin 2
Slide 6: Q2 FY24: Key Developments
Q2 FY24: Key Developments Consistent trajectory of improved profitability Financials Complex Generics Sales and EBITDA* Trajectory gSpiriva Gaining Diazepam Launched in 60,000 30.0% DPI momentum Rectal Gel US 47,421 49,392 50,000 40,912 42,446 43,303 25.0% Business Development 40,000 20.0% 30,000 18
Slide 7: Q2 FY24 Financial Snapshot
Q2 FY24 Financial Snapshot Sales Mix Key Financials INR in mn Sales (In INR mn and %) North Q2 FY24 Q2 FY23 Q1 FY24 America, 18,666 India, 16,915 37.8% Sales 49,392 40,912 47,421 34.2% 49,392 mn API, 2,684 EBITDA* 9,231 4,342 8,565 5.4% Growth Markets, ROW, EMEA, 4,377 Net Income 4,897 1,297 4,523 1
Slide 8: India: Outperforming market growth
India: Outperforming market growth India Region Formulations (IRF) has grown 8.9% ex Leveraging therapy leadership by adding 7 NLEM impact in Q2FY24 new divisions in last 12 months India Sales (INR mn) 16,915 15,841 16,384 #2 rank #3 rank #3 rank 15,213 14,786 Respiratory Diabetes Care Cardiac • 7,2
Slide 9: India: Amplifying our Core
India: Amplifying our Core Lupin prescription business is positioned to Enabling end to end healthcare ecosystem and access outperform IPM with key drivers in place for the patient Enhancing penetration and reach • Maximizing Chronic therapy focus CHC Portfolio catering to GI, VMS, Cough/cold therap
Slide 10: North America: Building Complex Gx Portfolio
North America: Building Complex Gx Portfolio Leadership: 4.4% TRx New product sales driving Growing Respiratory volume share in U.S.1 US growth portfolio US Sales ($mn) 213 #3 #1 159 177 175 181 22.9% 32.8% in the US1 in 48 products2 Albuterol Arfomoterol Q2 Q3 Q4 Q1 Q2 market share market share Mai
Slide 11: Other Markets: Key Highlights
Other Markets: Key Highlights Steady performance in developed markets Emerging Markets • Growth driven by higher Luforbec® and tender sales • BRL 74 mn sales in Q2 FY24 (growth EU • Strong growth in Germany and UK Brazil of 6% YoY) • Completed Medisol acquisition in • Rank 4th in reference market3 F
Slide 12: Innovation and Quality
Innovation and Quality R&D pivoting towards complex generics and Achieve Best-in-Class Quality biosimilars Substantial Capabilities to become CGx powerhouse Recent Track Record • Inhalation: Global presence with end to end capabilities Successful outcomes in last 4 inspections of MDIs, DPIs, Soft-Mi
Slide 13: Key Financial Metrics: Quarterly Trend
Key Financial Metrics: Quarterly Trend 2,500 15.0% R&D (INR mn) Capex (INR mn) Net debt/ Equity 13.0% 3,900 3,679 3,764 2,000 15.0% 3,376 11.0% 0.27 3,600 1,540 1,555 1,502 0.25 13.0% 3,300 2,896 3,050 1,500 1,345 9.0% 3,000 11.0% 2,700 1,171 0.20 2,400 9.0% 7.0% 2,100 7.0%1,000 5.0% 0.14 1,800 8.3%
Slide 14: P&L Highlights Q2 FY24
P&L Highlights Q2 FY24 YoY QoQ Amount in INR mn Q2FY24 % of Sales Q2FY23 % of Sales Q1FY24 % of Sales Growth Growth Sales 49,392 100.0% 40,912 100.0% 20.7% 47,421 100.0% 4.2% Other operating income 993 2.0% 544 1.3% 82.6% 719 1.5% 38.2% Total revenue 50,386 102.0% 41,456 101.3% 21.5% 48,141 101.5% 4
Slide 15: Lupin at a Glance
Lupin at a Glance
Slide 16: Lupin Today
Lupin Today Operating from a position of strength Global Presence Local Leadership Geographically Diverse (FY23 Sales) 13th Largest in 7th India Pharma Largest Generic 3 rd the US Market Rank 37% INDIA 8% Developed Company (by prescriptions3) Markets (by sales3) (by sales1) 32% Largest Largest South
Slide 17: Vision
Vision A pharmaceutical company focused on delivering high quality medicines to patients around the world Global Other United Developed India Region Emerging API States Markets Markets Evolving portfolio and Global operational Delivering innovative pipeline in Complex Global reach and scale as effic
Slide 18: Lupin's ESG Journey
Lupin’s ESG Journey Our Commitment to Responsible Business Practices, Sustainability, Environmental Stewardship and Risk Management Environment Enhancing targets and tracking for ESG • Adding renewable and biogenic capacities to To enhance and take additional targets in reduce Scope 1 and 2 emission
Slide 19: ESG: External Validation of progress made in 2023
ESG: External Validation of progress made in 2023 Committed to accountability and public disclosure of ESG initiatives and metrics • Lupin has made significant investment and progress in 2023 as an organization • Maintaining momentum towards continuously enhancing our ESG systems and processes Agenc
Slide 20: Lupin – Awards and Accolades
Lupin – Awards and Accolades Organizational Awards Leadership and Other Awards • ATD (Association of Talent • Vinita Gupta, named among India’s 20 Most Influential Women in Development) BEST Award Healthcare by 2022 BW Healthcare World • ‘Factories of the Future’ at the • ISO HSE certification audit
Slide 21: Thank You
youtube.com/c/LupinGlobal twitter.com/LupinGlobal linkedIn.com/company/lupin facebook.com/LupinWorld/ Thank You Registered Address 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai – 400055, India Phone: +91 22664 02323 | Fax: +91 22664 02051 | www.lupin.com